CA2290755A1 - Utilisation d'un complexe recepteur de proteine morphogenetique osseuse (bmp) a des fins de selection - Google Patents

Utilisation d'un complexe recepteur de proteine morphogenetique osseuse (bmp) a des fins de selection Download PDF

Info

Publication number
CA2290755A1
CA2290755A1 CA002290755A CA2290755A CA2290755A1 CA 2290755 A1 CA2290755 A1 CA 2290755A1 CA 002290755 A CA002290755 A CA 002290755A CA 2290755 A CA2290755 A CA 2290755A CA 2290755 A1 CA2290755 A1 CA 2290755A1
Authority
CA
Canada
Prior art keywords
leu
ser
glu
gly
bmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002290755A
Other languages
English (en)
Inventor
Jan Susan Rosenbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2290755A1 publication Critical patent/CA2290755A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

L'invention porte sur l'utilisation d'un récepteur de type II partagé entre des activines et des protéines morphogénétiques osseuses, conjugué à un récepteur de protéine morphogénétique osseuse de type I, pour sélectionner des agents de différenciation cellulaire. L'invention concerne en outre des cellules contenant un ADN codant pour ce récepteur, et cet ADN. Un procédé pour déterminer la capacité d'un composé de se lier à un nouveau complexe BMP et la capacité d'un composé d'essai à produire un signal après sa liaison avec ce complexe protéine et récepteur de BMP, et un procédé pour déterminer la concentration d'un ligand de récepteur de BMP dans un échantillon clinique utilisant un nouveau complexe BMP sont également décrits, ainsi qu'une cellule hôte co-transfectée avec un vecteur d'expression contenant une séquence d'ADN qui code pour les composants de ce complexe, ou des fragments solubles de ce dernier.
CA002290755A 1997-05-16 1998-05-13 Utilisation d'un complexe recepteur de proteine morphogenetique osseuse (bmp) a des fins de selection Abandoned CA2290755A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4676897P 1997-05-16 1997-05-16
US60/046,768 1997-05-16
PCT/US1998/009519 WO1998052038A1 (fr) 1997-05-16 1998-05-13 Utilisation d'un complexe recepteur de proteine morphogenetique osseuse (bmp) a des fins de selection

Publications (1)

Publication Number Publication Date
CA2290755A1 true CA2290755A1 (fr) 1998-11-19

Family

ID=21945289

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002290755A Abandoned CA2290755A1 (fr) 1997-05-16 1998-05-13 Utilisation d'un complexe recepteur de proteine morphogenetique osseuse (bmp) a des fins de selection

Country Status (6)

Country Link
EP (1) EP0981745A1 (fr)
JP (1) JP2002510198A (fr)
AU (1) AU7478298A (fr)
CA (1) CA2290755A1 (fr)
IL (1) IL132922A0 (fr)
WO (1) WO1998052038A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
DK2332977T3 (en) * 2004-07-23 2016-02-29 Acceleron Pharma Inc ActRII receptor polypeptides
AU2015200950B2 (en) * 2004-07-23 2017-04-27 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
EP2265603B1 (fr) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibiteurs de la voie de signalisation bmp
WO2014160203A2 (fr) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Inhibiteurs de bmp et leurs procédés d'utilisation
WO2016011019A1 (fr) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions et procédés d'inhibition de la bmp
AU2017338915A1 (en) * 2016-10-05 2019-04-18 Acceleron Pharma Inc. TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248554B1 (en) * 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
US6306622B1 (en) * 1994-11-04 2001-10-23 The Procter & Gamble Co. cDNA encoding a BMP type II receptor
US6210899B1 (en) * 1994-11-04 2001-04-03 The Procter & Gamble Company Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor

Also Published As

Publication number Publication date
WO1998052038A1 (fr) 1998-11-19
IL132922A0 (en) 2001-03-19
AU7478298A (en) 1998-12-08
JP2002510198A (ja) 2002-04-02
EP0981745A1 (fr) 2000-03-01

Similar Documents

Publication Publication Date Title
US5824504A (en) Human 7-transmembrane receptor and DNA
US6316408B1 (en) Methods of use for osetoprotegerin binding protein receptors
KR0144861B1 (ko) 인간 b세포 자극인자-2에 대한 수용체 단백질
CA2292339A1 (fr) Smad6 et ses utilisations
WO1999020758A1 (fr) Proteines tr11, tr11sv1 et tr11sv2 de type recepteur du facteur de necrose tumorale humain
JP2002508657A (ja) ２つのヒトｇタンパク質共役型レセプター：ｅｂｖ誘導性ｇｐｃｒ２（ｅｂｉ−２）およびｅｄｇ−１様ｇｐｃｒ
CA2220036A1 (fr) Recepteur de neuropeptides humain
CA2280290C (fr) Recepteurs de netrine
CA2173102C (fr) Sequence d'adn codant pour un recepteur de la proteine morphogenetique osseuse
CA2290040A1 (fr) La smad7 et ses utilisations
CA2290755A1 (fr) Utilisation d'un complexe recepteur de proteine morphogenetique osseuse (bmp) a des fins de selection
CA2204151C (fr) Adn complementaire codant pour un recepteur de type ii de proteines morphogenetiques osseuses (bmp)
CA2386029A1 (fr) P-glycoproteines provenant de <i>macaca fascicularis</i> et utilisations correspondantes
JP2003000270A (ja) 腫瘍抗原
JPH10150993A (ja) 新規ｇ−蛋白結合受容体ｈｌｔｅｘ１１
WO1998003534A1 (fr) Facteur composant du recepteur du peptide apparente au gene de la calcitonine (houdc44)
JPH10201482A (ja) カルシトニン遺伝子関連ペプチド受容体成分因子（ｈｏｕｄｃ４４）
EP0834565A2 (fr) Un récepteur, HUVCT36, couplé à une protéine G
AU748167B2 (en) Novel nucleic acid and polypeptide
CA2356243A1 (fr) Nouvelles proteines receptrices couplees aux proteines se liant a la guanosine triphosphate (gtp)
US7759066B2 (en) Molecule associating with intracellular C-terminal domain of receptor
CA2384981A1 (fr) Glycoproteines p et leurs utilisations
EP0837128A2 (fr) Récepteur humain couplé à la protéine G, HLYAZ61
JPH07258295A (ja) プロスタグランジンｄ受容体、その製造方法、その受容体をコードするｄｎａ、そのｄｎａからなるベクターおよびそのベクターで形質転換された宿主細胞
JP2003265176A (ja) ヒト腫瘍壊死因子δおよびε

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued